Pall Corp. has signed a commercial collaboration with RoosterBio Inc., for the co-development and marketing of complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). These systems aim to enable the biopharma industry to accelerate product development, reduce clinical translation timelines and help streamline the commercialization pathway for stem cell-based therapies.
 
Stem cell-based technologies are progressing rapidly through the clinic, but manufacturing of these therapeutics, including hMSCs, is significantly limited in scale. The alliance aims to provide bioprocess solutions for cell culture of low cost, translation-friendly hMSCs for development of Cell Therapy, Tissue Engineering, Drug Screening, and Regenerative Medicines.
 
Mario Philips, president, single-use technologies, stated, “Our vision is aligned with the customer requirements of large scale stem cell culture. Along with the RoosterBio hMSCs and media, the Pall solution offerings such as XRS 20 and Xpansion multiplate bioreactors, SoloHill microcarriers, and Allegro biocontainers enable our customers to grow stem cells on an industrially relevant scale.”
 
Jon Rowley, RoosterBio’s chief executive and technical officer, said, “Our mission at RoosterBio is to greatly increase the availability and accessibility of stem cell technologies to researchers and product developers across the globe. We are excited to be working with Pall and their innovative technology team to develop complete solutions for the simple and affordable generation of industrial quantities of hMSCs. Pall’s global team will be critical in driving rapid adoption of these systems on an international scale. This partnership will have a major impact on the pace of the Regenerative Medicine field.”